Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research.

Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma.

Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.

Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.

Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor.

Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.

Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC).

Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells.

Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research.

Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research.

HRX-0233 (HRX0233) is a potent and selective inhibitor of MAP2K4 (MKK4), a kinase involved in the stress-activated protein kinase (SAPK) signaling pathway. MAP2K4 plays a role in regulating cellular responses to stress, apoptosis, and tumorigenesis. HRX-0233 has shown particular promise in KRAS-mutant cancers, where it exhibits synergistic effects with RAS inhibitors, making it a potential candidate for combination therapy in these difficult-to-treat cancers.

Biricodar (VX-710) is a multidrug resistance (MDR) modulator that targets two key drug efflux transporters: P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP-1). These transporters are often overexpressed in cancer cells and contribute to multidrug resistance (MDR) by pumping chemotherapeutic drugs out of the cells, reducing their intracellular concentration and efficacy. Biricodar inhibits the function of Pgp and MRP-1, effectively chemosensitizing multidrug-resistant cancer cells and enhancing the effectiveness of chemotherapy agents. Its ability to reverse MDR makes it a promising candidate for improving cancer treatment outcomes.

The compound you are referring to is likely a dual inhibitor of p70S6K (S6K1) and Akt, two critical kinases in the PI3K/Akt/mTOR signaling pathway. This pathway is a central regulator of cell growth, proliferation, survival, and metabolism, and its dysregulation is frequently observed in cancers, including solid tumors and non-Hodgkin's lymphoma (NHL). A dual inhibitor targeting both p70S6K and Akt would offer a powerful therapeutic strategy to block this pathway at multiple nodes, potentially overcoming resistance mechanisms and improving treatment outcomes.

IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that specifically targets the interaction between interferon-alpha (IFN-α) and its receptor, interferon-alpha/beta receptor (IFNAR). This interaction is critical for initiating IFN-α signaling, which plays a key role in antiviral and immune responses. By blocking this interaction, IFN alpha-IFNAR-IN-1 hydrochloride inhibits IFN-α signaling and downstream responses, making it a valuable tool for studying IFN-α biology and its role in diseases such as autoimmune disorders and viral infections. It has demonstrated efficacy in inhibiting modified Vaccinia virus Ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3-L-differentiated plasmacytoid dendritic cell (pDC) cultures (BM-pDCs) with an IC50 of 2-8 µM.

STC-15 is a groundbreaking, orally bioavailable, highly selective inhibitor of METTL3, an RNA methyltransferase enzyme that plays a critical role in regulating gene expression through N6-methyladenosine (m6A) modification of RNA. METTL3 is implicated in the pathogenesis of various cancers, including acute myeloid leukemia (AML) and solid tumors. STC-15 represents the first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development, marking a significant milestone in the field of epitranscriptomics and cancer therapy.

Reversan (CBLC4H10) is a potent and nontoxic inhibitor of two major drug efflux transporters: multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (Pgp). These transporters are key players in multidrug resistance (MDR), a major obstacle in cancer chemotherapy, as they pump chemotherapeutic drugs out of cancer cells, reducing their intracellular concentration and efficacy. By inhibiting MRP1 and Pgp, Reversan can reverse drug resistance and enhance the effectiveness of chemotherapy agents. Its nontoxic profile makes it a promising candidate for overcoming MDR in cancer treatment.

Flecainide hydrochloride is a potent and orally active antiarrhythmic agent widely used in the treatment of various cardiac arrhythmias. It belongs to the class IC antiarrhythmic drugs, which are known for their strong sodium channel-blocking properties. Flecainide hydrochloride primarily works by inhibiting the cardiac fast inward sodium current (INa) and the rapid component of the delayed rectifier potassium current (IKr), leading to a prolongation of the action potential duration (APD) in both ventricular and atrial muscle fibers. Its unique electrophysiological effects make it particularly effective in managing certain types of arrhythmias, including fetal tachycardias.

Zelasudil is a Rho-associated coiled-coil kinase (ROCK) inhibitor with a specific binding affinity for ROCK2, a key enzyme in the Rho/ROCK signaling pathway. This pathway plays a critical role in regulating cellular processes such as cytoskeletal organization, cell motility, smooth muscle contraction, and gene expression. By selectively inhibiting ROCK2, Zelasudil modulates these processes, offering therapeutic potential for a variety of diseases characterized by fibrosis, inflammation, and vascular dysfunction, including pulmonary fibrosis, glaucoma, and cardiovascular diseases.

CMP-5 (PRMT5-IN-5) is a first-in-class, small-molecule inhibitor that specifically targets protein arginine methyltransferase 5 (PRMT5), an enzyme involved in epigenetic regulation and cellular signaling. PRMT5 catalyzes the symmetric dimethylation of arginine residues on histones and other proteins, playing a critical role in gene expression, cell proliferation, and survival. CMP-5 has shown remarkable specificity in blocking Epstein-Barr virus (EBV)-driven B-lymphocyte transformation and survival, while sparing normal B cells, making it a promising therapeutic candidate for EBV-associated cancers and other PRMT5-dependent diseases.

INF 195 is a potent and selective NLRP3 inflammasome inhibitor that has shown significant promise in preclinical studies for its ability to inhibit NLRP3-driven inflammatory responses, including macrophage pyroptosis and IL-1β release. By targeting the NLRP3 inflammasome, INF 195 has demonstrated therapeutic potential in conditions involving excessive inflammation, such as myocardial ischemia/reperfusion injury (IRI).

KIF18A-IN-6 (Compound 134) is a highly potent and orally active KIF18A inhibitor with significant potential for cancer therapy. Its ability to disrupt mitosis and induce apoptosis in cancer cells makes it a promising candidate for targeting chromosomally unstable tumors and advancing cancer research.

BI-1750 is a highly selective and stable fluorogenic substrate designed for Cathepsin C (CatC), a lysosomal cysteine protease involved in various physiological and pathological processes. Its unique properties make it a powerful tool for studying CatC activity in both research and drug development contexts.

The transferrin receptor (TfR) is a transmembrane glycoprotein whose function is to mediate iron absorption through its interaction with transferrin. In normal cells, the expression level of the receptor is low, and the expression of the transferrin receptor in cells (chronic lymphocytic non-Hodgkin tumors) is significantly increased due to the increased demand for iron in rapidly growing cells [2-4]. At present, two transferrin receptors, TfR1 and TfR2, have been found, both of which are type II transmembrane glycoproteins that bind to transferrin and mediate iron absorption. TfR1 is expressed in many cells (such as red blood cells, hepatocytes, monocytes), and can change its conformation according to the change of environmental pH, and convert the results of conformational change into a change in the binding strength of transferrin. TfR2 is mainly expressed in the liver, and its main function may be to regulate and maintain the homeostasis of iron ions in the body, while its role in transporting iron ions to rapidly dividing tissues is weak. Using the effective targeting function of transferrin receptor, the cross-linking of transferrin and drugs can improve the specific binding ability of drugs, but also improve the effect.

ABX-002 is a novel CNS-penetrant TR-B agonist prodrug with significant potential for treating demyelinating disorders (e.g., multiple sclerosis), neuroinflammatory diseases (e.g., ALS, Alzheimer's), and neurodegenerative diseases (e.g., Parkinson's, Huntington's). Its ability to promote remyelination, reduce inflammation, and protect neurons makes it a promising therapeutic candidate for a range of CNS disorders.

FAP-IN-2 is a 99mTc-labeled FAPI inhibitor designed for tumor imaging. It targets fibroblast activation protein (FAP) in the tumor microenvironment, enabling high-contrast SPECT imaging of FAP-expressing tumors. Its specificity, stability, and imaging capabilities make it a valuable tool for cancer diagnosis, staging, and research. Additionally, it has potential theragnostic applications in oncology.

GN13 is a potent, selective, and cell-permeable inhibitor of Gαs, with a strong binding affinity for the active, GTP-bound state of Gαs (KD = 0.19 μM). Its high selectivity and ability to penetrate cells make it a powerful tool for studying Gαs signaling in both basic research and potential therapeutic applications.

Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer.

The statement suggests that CN009543V enhances tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) through downstream signaling pathways.

Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research.

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.